ARIA Sensing Unveils "Hydrogen" — The World’s First 3D UWB Radar System-On-Chip
ARIA Sensing proudly announces the launch of "Hydrogen," a groundbreaking Ultra-Wideband (UWB) Radar System-On-Chip (SoC) that sets a new industry benchmark as the first to offer 3D beamforming with programmable bandwidth up to 1.8 GHz.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218452155/en/
Hydrogen, the world's first UWB Radar SoC for 3D detection, of the Italian company ARIA Sensing (Photo: Business Wire)
The "Hydrogen" SoC introduces advanced waveforms supporting both single-pulse and pulse-compression capabilities, delivering unparalleled precision in radar sensing applications. Equipped with two integrated RISC-V microprocessors, the chip ensures robust performance and flexibility for a variety of use cases.
Key features of "Hydrogen" include:
- 4Tx and 4Rx UWB channels: Allowing flexible and scalable array configurations for optimized 3D imaging and radar detection.
- Advanced 3D Beamforming: Providing accurate depth perception and spatial resolution for sophisticated sensing environments.
- Programmable Bandwidth (up to 1.8 GHz): Enhancing adaptability across different sensing applications and environments.
ARIA Sensing offers four modular solutions tailored for both 2D and 3D radar applications, ensuring versatility and seamless integration into diverse markets, including automotive, industrial automation, and smart home technologies.
"Hydrogen represents a paradigm shift in radar technology, combining cutting-edge UWB advancements with compact SoC design. We are excited to see how this innovation will redefine radar sensing applications," said Alessio Cacciatori, Founder and CEO at ARIA Sensing.
About ARIA Sensing
ARIA Sensing is a leader in advanced radar technology, providing next-generation solutions that drive innovation in sensing applications. Our mission is to deliver state-of-the-art technology that meets the evolving needs of global industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241218452155/en/
Contacts
For media inquiries, please contact:
Alessio Cacciatori, CEO
alessio.cacciatori@ariasensing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hyatt Discloses Exclusive Discussions With Playa Hotels & Resorts N.V.23.12.2024 13:20:00 EET | Press release
Hyatt Hotels Corporation (the “Company” or “Hyatt”) (NYSE: H) today disclosed it has executed an exclusivity agreement with Playa Hotels & Resorts N.V. (“Playa”) (NASDAQ: PLYA) under which Playa has agreed to negotiate exclusively with Hyatt regarding potential strategic alternatives, which may include the acquisition of Playa by Hyatt. Mark S. Hoplamazian, President and Chief Executive Officer of Hyatt, said, "Playa has been a valuable partner for many years, is one of the world’s strongest operators of all-inclusive resorts, and owns a premier portfolio of high-quality, high-end all-inclusive resorts in iconic locations and key markets across the Caribbean and Mexico. Strategic alternatives under consideration could have compelling strategic merit to add new incremental durable fee streams for Hyatt. We remain steadfastly committed to our asset-light business model and if this process continues, we will continue to map out a clear path for an asset-light outcome for any strategic alt
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference23.12.2024 13:00:00 EET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere.” The Company’s CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change
Moutai's Global Brand Cultural Event Concludes in Italy22.12.2024 19:10:00 EET | Press release
The 2024 Global Brand Cultural Event hosted by Kweichow Moutai Group recently concluded successfully in Italy. Leveraging liquor as a cultural bridge between East and West, the event charted new pathways and milestones for Chinese brands, exemplified by Kweichow Moutai Group, in their global outreach. It also fostered deeper cultural exchange and mutual understanding between China and Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241222852417/en/ Gao Shan introduced Moutai to the guests at the event in Rome. (Photo: Business Wire) As part of the event, Moutai organized two grand themed tasting dinners in Milan and Rome. Gao Shan, Chairman of the Labor Union of Kweichow Moutai Distillery (Group) Co., Ltd., highlighted Italy's longstanding support in Moutai’s international journey, noting that the brand has been exported to Italy since the 1970s. Quoting Italian President Sergio Mattarella during his visit to China, Ga
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 20:41:00 EET | Press release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom